Takaisin

Efficacy of semaglutide in the treatment of obesity in adolescents

Näytönastekatsaukset
Bianca Arrhenius
17.11.2026

Level of evidence: B

Once-weekly subcutaneous semaglutide 2.4 mg in combination with lifestyle intervention probably leads to a clinically significant reduction in BMI standard deviation score (-1.0 compared to placebo) in adolescents with obesity, during a follow-up period of 68 weeks.

The level of evidence is downgraded due to risk of bias (possible publication bias, only one study with a relatively small sample).

No major safety concerns were identified, but long-term safety is undetermined.

Table 1. Description of the included studies
Reference Study type Population Intervention and comparison Outcomes Risk of bias
RCT=randomized controlled trial; SR=systematic review; MA=meta-analysis
«Weghuber D, Barrett T, Barrientos-Pérez M, et al. ...»1 Randomized controlled trial Adolescents aged 12–17 years with obesity (BMI ≥95th percentile) or overweight (BMI+ ≥ 85th percentile) and some comorbidity.
N=201 (semaglutide 133 / placebo 67). Multicenter study in US, Europe and Asia; outpatient setting.
Intervention: once-weekly subcutaneous semaglutide 2.4 mg + lifestyle intervention for 68 weeks.
Comparison: placebo injection + lifestyle intervention for 68 weeks.
Primary: % change in BMI to week 68. Secondary: proportion achieving ≥5% weight loss, change in cardiometabolic risk factors (waist circumference, HbA1c, lipids except HDL-C, ALAT), adverse events. Moderate
Table 2. Additional comments for included studies
Reference Comments
«Weghuber D, Barrett T, Barrientos-Pérez M, et al. ...»1 High number of study completers: A total of 132 participants (99%) in the semaglutide group and 64 (96%) in the placebo group completed the trial; at week 68, treatment had been completed by 120 participants (90%) in the semaglutide group and 60 participants (90%) in the placebo group.
Weight regain was seen during a seven week off-treatment follow-up.
Treatment also improved several cardiometabolic risk markers (waist circumference, HbA1c, ALAT, and lipid profile). The main adverse effects were gastrointestinal (nausea, vomiting, diarrhea), which were mostly mild to moderate. Cholelithiasis occurred more frequently in the semaglutide group (4 %) than in placebo (0 %). Serious adverse events were infrequent and comparable between groups (11 % vs 9 %).
Weight-related quality of life: semaglutide was associated with improvements in IWQOL-Kids total score and the physical comfort domain score at week 68. The improvement in the total score was driven mainly by the change in the physical comfort domain score. No differences between groups were observed for the other IWQOL-Kids domain scores for the treatment policy estimand or for any IWQOL-Kids domain scores for the trial product estimand.
Industry-funded study, only one RCT exists, introducing risk of bias.

Results

Table 3. BMI change, absolute and standard deviation score
Reference Number of studies and number of patients (I/C) Follow-up time Mean BMI change, I Mean BMI change, C Relative effect (95% CI)
Level of evidence: moderate. Evidence is downgraded due to risk of bias (possible publication bias, only one study with a relatively small sample).
I= intervention; C=comparison; CI=confidence interval
«Weghuber D, Barrett T, Barrientos-Pérez M, et al. ...»1 I=133 / C=67 68 weeks -5.8 +0.1 -6.0 (-7.3 to -4.6)
Change in BMI standard deviation score
Change in BMI standard deviation score
Relative change in BMI standard deviation score
-1.1 -0.1 -1.0 (-1.3 to -0.8)
Table 4. Change in body weight
Reference Number of studies and number of patients (I/C) Follow-up time Mean change in body weight, kg (%) I Mean change in body weight, kg (%) C Relative effect (95% CI)
Level of evidence: moderate. Evidence is downgraded due to risk of bias (possible publication bias, only one study with a relatively small sample).
I= intervention; C=comparison; CI=confidence interval
«Weghuber D, Barrett T, Barrientos-Pérez M, et al. ...»1 I=133 / C=67) 68 weeks -15.3 kg (-14.7%) +2.4 kg (+2.7%) -17.7% (-21.1% to -13.7%)
Table 5. ≥5% weight loss
Reference Number of studies and number of patients (I/C) Follow-up time Absolute number of events (%), I Absolute number of events, (%) C Odds ratio (95% CI)
Level of evidence: moderate. Evidence is downgraded due to risk of bias (possible publication bias, only one study with a relatively small sample).
I= intervention; C=comparison; CI=confidence interval
«Weghuber D, Barrett T, Barrientos-Pérez M, et al. ...»1 I=133 / C=67) 68 weeks 95/131 (73%) 11/62 (18%) OR 14.0 (95% CI 6.3–31.0)

References

  1. Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med 2022;387(24):2245-2257 «PMID: 36322838»PubMed